These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 9455569)
21. Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity. Quirino T; Bonfanti P; Arcidiacono M; Pusterla L; Cagni A; Scaglione F; Milazzo F Biomed Pharmacother; 1999 Jun; 53(5-6):286-7. PubMed ID: 10424252 [TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection. Wong YY; Rakasz EG; Gasper DJ; Friedrich TC; Trepanier LA Toxicology; 2016 Aug; 368-369():10-18. PubMed ID: 27565715 [TBL] [Abstract][Full Text] [Related]
32. A middle-aged man with newly diagnosed HIV infection and rash. Njoku P; Tate T; Zadeh S; Hauck E; Chaudhry A; Lo-Blais B; Nesbitt L; Sanders CV; Lopez FA J La State Med Soc; 2007; 159(3):131-5. PubMed ID: 17694932 [TBL] [Abstract][Full Text] [Related]
33. Successful desensitization of two patients who previously developed Stevens-Johnson syndrome while receiving trimethoprim-sulfamethoxazole. Douglas R; Spelman D; Czarny D; O'Hehir RE Clin Infect Dis; 1997 Dec; 25(6):1480. PubMed ID: 9431406 [No Abstract] [Full Text] [Related]
34. Trimethoprim is a potassium-sparing diuretic like amiloride and causes hyperkalemia in high-risk patients. Perazella MA Am J Ther; 1997; 4(9-10):343-8. PubMed ID: 10423629 [TBL] [Abstract][Full Text] [Related]
35. Rash and elevated creatine kinase in a deployed soldier. Schmidt TW; Garfinkle M; Battafarano DF Mil Med; 2014 Feb; 179(2):e245-8. PubMed ID: 24491625 [TBL] [Abstract][Full Text] [Related]
36. Comparisons of oxidative metabolism and reductive capacity in sulfonamide-tolerant and -intolerant patients with human immunodeficiency virus. Lehmann DF; Holohan PD; Blair DC J Clin Pharmacol; 1996 Dec; 36(12):1149-53. PubMed ID: 9013372 [TBL] [Abstract][Full Text] [Related]
37. Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Veenstra J; Veugelers PJ; Keet IP; van der Ven AJ; Miedema F; Lange JM; Coutinho RA Clin Infect Dis; 1997 May; 24(5):936-41. PubMed ID: 9142796 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of desensitization to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Piketty C; Gilquin J; Kazatchkine MD J Infect Dis; 1995 Aug; 172(2):611. PubMed ID: 7622921 [No Abstract] [Full Text] [Related]